Ionis Pharmaceuticals IONS Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's cash & equivalents?
- Ionis Pharmaceuticals (IONS) reported cash & equivalents of $173.38M in Q1 2026.
- How has Ionis Pharmaceuticals's cash & equivalents changed year-over-year?
- Ionis Pharmaceuticals's cash & equivalents decreased by 34.4% year-over-year, from $264.19M to $173.38M.
- What is the long-term trend for Ionis Pharmaceuticals's cash & equivalents?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's cash & equivalents has grown at a -1.3% compound annual growth rate (CAGR), from $397.66M to $372.26M.
- What does cash & equivalents mean?
- The amount of cash and easily convertible assets the company has on hand.
- How do you interpret cash & equivalents?
- Higher levels provide a safety buffer for clinical trials and operations, while declining levels may signal a need for future capital raises.
- How does cash & equivalents compare across companies?
- Critical for biotech companies to ensure runway for long-term drug development.